Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
Regulated Information Ghent, BELGIUM – 23 April 2019 (18:00 CEST) – Sequana Medical NV (“Sequana Medical” or the “Company“) (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces that its Annual...
Read More
Ghent, BELGIUM – 4 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces its business highlights and financial results for the year ended 31 December 2018, prepared...
Read More
Regulated Information Ghent, BELGIUM – 26 March 2019 (19:00 CET) – Sequana Medical NV [Euronext Brussels: SEQUA] (“Sequana Medical”, the “Company”) today invited the holders of securities issued by the Company to attend an extraordinary shareholders’ meeting before notary public on Thursday 25 April 2019. The agenda items of the extraordinary shareholders’ meeting relate to...
Read More
Ghent, BELGIUM – 18 March 2019 (5.30 PM CET) – Today, Sequana Medical NV (“Sequana Medical” or the “Company“), announces the end of the stabilisation period in the framework of the initial public offering of new shares of the Company with the admission of all of its shares to trading on the regulated market of...
Read More
Ghent, BELGIUM – 1 March 2019 – Within the framework of the initial public offering of new shares of Sequana Medical NV (“Sequana Medical” or the “Company“), with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol “SEQUA” (the “Offering“), KBC Securities NV/SA has been...
Read More
Ghent, BELGIUM – 25 February 2019 – Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today in accordance with article 14 of the Belgian Act of...
Read More
Ghent, BELGIUM – 20 February 2019 – Within the framework of the initial public offering of new shares of Sequana Medical NV (“Sequana Medical” or the “Company“), with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol “SEQUA” (the “Offering“), KBC Securities NV/SA has been...
Read More
Ghent, BELGIUM – 18 February 2019 – Sequana Medical NV – Euronext Brussels SEQUA (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today in accordance with article 15 of...
Read More
1 5 6 7

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES